Agreed - I'm certainly waiting to see what deals are realised off the back of the US patent. More broadly, research into exosomes continues to grow at an accelerating pace - which is positive for the pick and shovel play in Exopharm. I'd also note that EX1 is presenting at the Biotech Showcase, which is taking place over 10-12 Jan. Immugene and Radiopharm are also presenting there - will be interesting to see any company release on what will be presented.
EX1 Price at posting:
49.0¢ Sentiment: Buy Disclosure: Held
